Invasive cribriform breast carcinomas in patients with grade 1 and stage IIA (T2 N0 M0) breast cancer strongly express the v3 and v6, but not the v4 isoforms of the metastatic marker CD44

Neoplasma

Volumn 55, Issue 3, 2008, Pages 246-255

  Saleh, F ^a   Reno, W ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

CD44v3, v4, and v6 isoforms; Invasive cribriform breast carcinoma; Kuwait

Indexed keywords

CD44V ANTIGEN; CD44V3 ANTIGEN; CD44V4 ANTIGEN; CD44V6 ANTIGEN; ISOPROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG; HERMES ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER STAGING; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; INVASIVE CRIBRIFORM BREAST CARCINOMA; PAPILLARY CARCINOMA; PEROXIDASE ANTIPEROXIDASE COMPLEX; QUANTITATIVE ANALYSIS; BREAST TUMOR; METABOLISM; PATHOLOGY; PROGNOSIS;

ANTIGENS, CD44; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM STAGING; PROGNOSIS; PROTEIN ISOFORMS; TUMOR MARKERS, BIOLOGICAL;

EID: 49049108219     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. PAGE DL, DIXON JM, ANDERSON TJ, et al. Invasive cribriform carcinoma of the breast. Histopathology 1983; 7: 525-536
2. VENABLE JG, SCHWARTZ AM, SILVERBERG SG. Infiltrating cribriform carcinoma of the breast: a distinctive clinicopathologic entity. Hum Pathol 1990; 21: 333-338
3. ELLIS I, GALEA M, BROUGHTON N, et al. Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up. Histopathology 1992; 20: 479-489
4. SHOUSHA S, SCHOENFELD A, MOSS J, et al. Light and electron microscopic study of an invasive cribriform carcinoma with extensive microcalcification developing in a breast with silicone augmentation. Ultrastruct Pathol 1994; 18: 519-523
5. JOENSUU H, KLEMI PJ, TOIKKANEN S, et al. Glycoprotein CD44 expression and its association with survival in breast cancer. Am J Pathol 1993; 143: 867-874
6. FRIEDRICHS K, FRANKE F, LISBOA BW, et al. CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer. Cancer Res 1995; 55: 5424-5433
7. KAUFMANN M, HEIDER KH, SINN HP, et al. CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet 1995; 345: 615-619
8. GURIEC N, MARCELLIN L, GAIRARD B, et al. CD44 exon 6 expression as a possible early prognostic factor in primary node negative breast carcinoma. Clin Exp Metastasis 1996; 14: 434-439
9. BANKFALVI A, TERPE HJ, BREUKELMANN D, et al. Gains and losses of CD44 expression during breast carcinogenesis and tumour progression. Histopathology 1998; 33: 107-116
10. FOEKENS JA, DALL P, KLIJN JG, et al. Prognostic value of CD44 variant expression in primary breast cancer. Int J Cancer 1999; 84: 209-215 (Pubitemid 29256743)
11. JALKANEN S, BARGATZE RF, de los TOYOS J, et al. Lymphocyte recognition of high endothelium: antibodies to distinct epitopes of an 85-95-kD glycoprotein antigen differentially inhibit lymphocyte binding to lymph node, mucosal, or synovial endothelial cells. J Cell Biol 1987; 105: 983-990
12. YASUDA M, NAKANO K, YASUMOTO K, et al. CD44: functional relevance to inflammation and malignancy. Histol Histopathol 2002; 17: 945-950
13. THANAKIT V, SAMPATANUKUL P, RUANGVEJVO-RACHAI P, et al. The association of co-expression of CD44v4/MMP-9 with different nodal status in high-grade breast carcinoma patients. J Med Assoc Thai 2005; 88: S30-5.
14. BOURGUIGNON LY, SINGLETON PA, ZHU H, et al. Hyaluronan-mediated CD44 interaction with RhoGEF and Rho kinase promotes Grb2-associated binder-1 phosphorylation and phosphatidylinositol 3-kinase signaling leading to cytokine (macrophage-colony stimulating factor) production and breast tumour progression. J Biol Chem 2003; 278: 29420-29434
15. BOURGUIGNON LY, ZHU H, SHAO L, et al. CD44 interaction with tiam1 promotes Rac1 signaling and hyaluronic acid-mediated breast tumour cell migration. J Biol Chem 2000; 275: 1829-1838 (Pubitemid 30060806)
16. SINN HP, HEIDER KH, SKROCH-ANGEL P, et al. Human mammary carcinomas express homologues of rat metastasis-associated variants of CD44. Breast Cancer Res Treat 1995; 36: 307-313
17. SCHUMACHER U, HORNY HP, HORST HA, et al. A CD44 variant exon 6 epitope as a prognostic indicator in breast cancer. Eur J Surg Oncol 1996; 22: 259-261 (Pubitemid 26229676)
18. TEMPFER C, LOSCH A, HEINZL H, et al. Prognostic value of immunohistochemically detected CD44 isoforms CD44v5, CD44v6 and CD44v7-8 in human breast cancer. Eur J Cancer 1996; 32A: 2023-2025
19. CHARPIN C, GARCIA S, BOUVIER C, et al. Automated and quantitative immunocytochemical assays of CD44v6 in breast carcinomas. Hum Pathol 1997; 28: 289-296 (Pubitemid 27106080)
20. FICHTNER I, DEHMEL A, NAUNDORF H, et al. Expression of CD44 standard and isoforms in human breast cancer xenografts and shedding of soluble forms into serum of nude mice. Anticancer Res 1997; 17: 3633-3645
21. HEFLER L, TEMPFER C, HAEUSLER G, et al. Cytosol concentrations of CD44 isoforms in breast cancer tissue. Int J Cancer 1998; 79: 541-545
22. LACKNER C, MOSER R, BAUERNHOFER T, et al. Soluble CD44 v5 and v6 in serum of patients with breast cancer. Correlation with expression of CD44 v5 and v6 variants in primary tumours and location of distant metastasis. Breast Cancer Res Treat 1998; 47: 29-40.
23. SNEATH RJ, MANGHAM DC. The normal structure and function of CD44 and its role in neoplasia. Mol Pathol 1998; 51: 191-200.
24. WEI Q, ZHANG L, ZHOU J. Significance of microvessel quantity in metastasis of invasive breast carcinoma. Bull Hunan Med Univ 1998; 23: 243-245
25. BANKFALVI A, TERPE HJ, BREUKELMANN D, et al. Immunophenotypic and prognostic analysis of E-cadherin and beta-catenin expression during breast carcinogenesis and tumour progression: a comparative study with CD44. Histopathology 1999; 34: 25-34.
26. KALISH ED, IIDA N, MOFFAT FL, et al. A new CD44V3-containing isoform is involved in tumour cell growth and migration during human breast carcinoma progression. Front Biosci 1999; 4: A1-8.
27. DENG Y, MA W, FANG X, et al. The relationship of expression of CD44v6 with metastasis and prognosis in breast cancer. Chin J Surg 2000; 38: 451-452
28. RUIBAL A, SCHNEIDER J, del RIO MC, et al. Expression of the adhesion molecule CD44v6 in infiltrating ductal carcinomas of the breast is associated with hormone dependence. Our experience with 168 cases. Rev Esp Med Nuc 2000; 19: 350-355
29. BERNER HS, NESLAND JM. Expression of CD44 isoforms in infiltrating lobular carcinoma of the breast. Breast Cancer Res Treat 2001; 65: 23-29 (Pubitemid 32163496)
30. KOPP R, CLASSEN S, WOLF H, et al. Predictive relevance of soluble CD44v6 serum levels for the responsiveness to second line hormone- or chemotherapy in patients with metastatic breast cancer. Anticancer Res 2001; 21: 2995-3000.
31. HE JH, LIANG XM, HOU JH, et al. Study of CD44v6 protein expression in intraductal papilloma and its malignant transformation of breast. Aizheng 2002; 21: 615-618
32. NIU RF, ZHANG J, HUANG JY. Expression of CD44v6 before and after chemotherapy in patients with breast cancer and its significance. Aizheng 2002; 21: 71-74
33. BERNER HS, SUO Z, RISBERG B, et al. Clinicopathological associations of CD44 mRNA and protein expression in primary breast carcinomas. Histopathology 2003; 42: 546-554 (Pubitemid 36688148)
34. RY J, KRUCZAK A, LACKOWSKA B, et al. The role of CD44v3 expression in female breast carcinomas. Pol J Pathol 2003; 54: 243-247 (Pubitemid 38233129)
35. ZUO WS, WEI L, WANG XW, et al. Expression of adhesive molecule CD44v6 and p53 gene in breast cancer tissues and its relation with DNA ploidy. Aizheng 2004; 23: 1418-1422
36. AUVINEN P, TAMMI R, TAMMI M, et al. Expression of CD 44 s, CD 44 v 3 and CD 44 v 6 in benign and malignant breast lesions: correlation and colocalization with hyaluronan. Histopathology 2005; 47: 420-428
37. BASSAROVA AV, TORLAKOVIC E, SEDLOEV T, et al. Simultaneous bilateral breast carcinoma: Histopathological characteristics and CD44/catenin-cadherin profile. Histol Histopathol 2005; 20: 791-799
38. MA W, DENG Y, ZHOU L. The prognostic value of adhesion molecule CD44v6 in women with primary breast carcinoma: a clinicopathologic study. Clin Oncol 2005; 17: 258-263
39. ELSTON EW, ELLIS IO. Method for grading breast cancer. J Clin Pathol 1993; 46: 189-190
40. th Ed. Lyon: IARC Press, 2003, 9-110.
41. DIAB SG, CLARK GM, OSBORNE CK, et al. Tumour characteristics and clinical outcome of tubular and mucinous breast carcinomas. J Clin Oncol 1999; 17: 1442-1448 (Pubitemid 29220850)
42. NORRIS HJ, TAYLOR HB. Prognosis of mucinous (gelatinous) carcinoma of the breast. Cancer 1965; 18: 879-885
43. KOMAKI K, SAKAMOTO G, SUGANO H, et al. Mucinous carcinoma of the breast in Japan. A prognostic analysis based on morphologic features. Cancer 1988; 61: 989-996
44. FENTIMAN IS, MILLIS RR, SMITH P, et al. Mucoid breast carcinomas: histology and prognosis. Br J Cancer 1997; 75: 1061-1065
45. ASHIKARI R, HUVOS AG, URBAN JA, et al. Infiltrating lobular carcinoma of the breast. Cancer 1973; 31: 110-116
46. SILVERSTEIN MJ, LEWINSKY BS, WAISMAN JR, et al. Infiltrating lobular carcinoma. Is it different from infiltrating duct carcinoma? Cancer 1994; 73: 1673-1677
47. TOIKKANEN S, PYLKKANEN L, JOENSUU H. Invasive lobular carcinoma of the breast has better short- and long-term survival than invasive ductal carcinoma. Br J Cancer 1997; 76: 1234-1240
48. MAIER WP, ROSEMOND GP, GOLDMAN LI, et al. A ten year study of medullary carcinoma of the breast. Surg Gynecol Obstet 1977; 144: 695-698 (Pubitemid 8195975)
49. BLACK CL, MORRIS DM, GOLDMAN LI, et al. The significance of lymph node involvement in patients with medullary carcinoma of the breast. Surg Gynecol Obstet 1983; 157: 497-499 (Pubitemid 14201124)
50. RAPIN V, CONTESSO G, MOURIESSE H, et al. Medullary breast carcinoma. A reevaluation of 95 cases of breast cancer with inflammatory stroma. Cancer 1988; 61: 2503-2510
51. WARGOTZ ES, SILVERBERG SG. Medullary carcinoma of the breast: a clinicopathologic study with appraisal of current diagnostic criteria. Hum Pathol 1988; 19: 1340-1346
52. JENSEN ML, KIAER H, ANDERSEN J, et al. Prognostic comparison of three classifications for medullary carcinomas of the breast. Histopathology 1997; 30: 523-532
53. PEDERSON L, LARSEN JK, CHRISTENSEN IJ, et al. DNA ploidy and S-phase fraction in medullary carcinoma of the breast - a flow cytometric analysis using archival material. Breast Cancer Res Treat 1994; 29: 297-306. (Pubitemid 24135825)
54. CORADINI D, DAIDONE MG. Biomolecular prognostic factors in breast cancer. Curr Opin Obstet Gynecol 2004; 16: 49-55. (Pubitemid 38241542)
55. HSU YH, SHAW CK. Expression of p53, DCC, and HER-2/neu in mucinous carcinoma of the breast. Kao Hsiung I Hsueh Ko Hsueh Tsa Chih 2005; 21: 197-202.
56. JALAVA P, KUOPIO T, HUOVINEN R, et al. Immunohistochemical staining of estrogen and progesterone receptors: aspects for evaluating positivity and defining the cutpoints. Anticancer Res 2005; 25: 2535-2542
57. SHERIDAN C, KISHIMOTO H, FUCHS RK, et al. CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 2006; 8: R59.
58. BOURGUIGNON LY, GUNJA-SMITH Z, IIDA N, et al. CD44v(3,8-10) is involved in cytoskeleton-mediated tumour cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells. J Cell Physiol 1998; 176: 206-215
59. REGIDOR PA, CALLIES R, REGIDOR M, et al. Expression of the CD44 variant isoforms 6 and 4/5 in breast cancer. Correlation with established prognostic parameters. Arch Gynecol Obstet 1996; 258: 125-135
60. RUIBAL A, ARIAS JI, DEL RIO MC, et al. Histological grade in breast cancer: association with clinical and biological features in a series of 229 patients. Int J Biol Markers 2001; 16: 56-61.
61. DIAZ LK, ZHOU X, WRIGHT ET, et al. CD44 expression is associated with increased survival in node-negative invasive breast carcinoma. Clin Cancer Res 2005; 11: 3309-3314
62. LYZAK JS, YAREMKO ML, RECANT W, et al. Role of CD44 in nonpalpable T1a and T1b breast cancer. Hum Pathol 1997; 28: 772-778 (Pubitemid 27298960)